Published in final edited form as:

Lancet Infect Dis. 2014 April ; 14(4): 308–318. doi:10.1016/S1473-3099(13)70342-6.

Epidemiological characteristics of hand-foot-and-mouth disease in China, 2008-2012

Weijia Xing[#], Qiaohong Liao[#], Cécile Viboud[#], Jing Zhang[#], Junling Sun, Joseph T Wu, Zhaorui Chang, Fengfeng Liu, Vicky J Fang, Yingdong Zheng, Benjamin J Cowling, Jay K Varma, Jeremy J Farrar, Gabriel M Leung, and Hongjie Yu

Division of Infectious Disease, Key Laboratory of Surveillance and Early-warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China (W Xing PhD, Q Liao MD, J Zhang MD, J Sun PhD, Zhaorui Chang MD, F Liu MD, H Yu MD); Fogarty International Center, National Institutes of Health, Bethesda, MD, USA (C Viboud PhD); Division of Epidemiology and Biostatistics, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China (B J Cowling PhD, J T Wu PhD, V J Fang MPhil, Prof G M Leung MD); School of Public Health, Peking University, Health Science Center, Beijing, China (Y Zheng PhD); New York City Department of Health and Mental Hygiene, New York, USA (J K Varma MD); Oxford University Clinical Research Unit – Wellcome Trust Major Overseas Programmes, Vietnam (Prof J J Farrar PhD); ISARIC, Centre for Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom (Prof J J Farrar PhD); Department of Medicine, National University of Singapore, Singapore (Prof J J Farrar PhD); The Li Ka Shing Oxford Global Health Programme and Wellcome Trust (Prof J J Farrar PhD)

[#] These authors contributed equally to this work.

Summary

Background—Hand-foot-and-mouth disease (HFMD) is a common childhood illness caused by enteroviruses. Increasingly it imposes a substantial disease burden throughout East and Southeast Asia. To better inform vaccine and other interventions, we characterized the epidemiology of HFMD in China based on enhanced surveillance.

Methods—We extracted epidemiological, clinical and laboratory data from reported HFMD cases during 2008–2012 and compiled climatic, geographic and demographic information. All analyses were stratified by age, disease severity, laboratory confirmation status and enterovirus subtype.

Findings—The surveillance registry captured 7,200,092 probable HFMD cases (annualized incidence, 1.2 per 1,000), of whom 3.7% were laboratory-confirmed and 0.03% died. Incidence and mortality were highest in children aged 12–23 months (in 2012: 38.2 cases per 1,000 and 1.5 death per 100,000). Median durations from onset to diagnosis and death were 1.5 days and 3.5

Correspondence to: Prof Gabriel M Leung, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR, China gmleung@hku.hk or Dr Hongjie Yu, Division of Infectious Disease, Key Laboratory of Surveillance and Early-warning on Infectious Disease, Chinese Center for Disease Control and Prevention, No. 155 Changbai Road, Changping district, Beijing, China yuhj@chinacdc.cn.

Competing Interests The authors have no competing interests to declare.

days respectively. The risk of cardiopulmonary or neurological complications was 1·1% and the severe-case fatality risk was 3·0%, with >90% of deaths associated with enterovirus 71. HFMD peaked annually in June in the North, whereas Southern China experienced semi-annual outbreaks in May and September/October. Geographic differences in seasonal patterns were weakly associated with climate and demographic factors (variance explained 8–23% and 3–19%, respectively).

Interpretation—This is the largest population-based study to date of the epidemiology of HFMD. Future mitigation policies should take full account of the heterogeneities of disease burden identified. Additional epidemiologic and serologic studies are warranted to elucidate local HFMD dynamics and immunity patterns and optimize interventions.

Funding—China–US Collaborative Program on Emerging and Re-emerging Infectious Diseases; World Health Organization; The Li Ka Shing Oxford Global Health Programme and Wellcome Trust; Harvard Center for Communicable Disease Dynamics; Health and Medical Research Fund, Government of the Hong Kong Special Administrative Region.

Keywords

Hand, Foot and Mouth Disease; Enterovirus 71; Coxsackie virus A16; Epidemiology; Disease burden; Seasonality

Introduction

Hand-foot-and-mouth disease (HFMD) is a common infectious condition caused by a variety of enteroviruses, with enterovirus 71 (EV-A71) and Coxsackie virus A16 (CA-V16) being the most commonly reported.¹ Children under five years are particularly prone to HFMD, and most patients show self-limiting illness typically including fever, skin eruptions on hands and feet, and vesicles in the mouth. However, a small proportion has been known to rapidly develop neurological and systemic complications that can be fatal, particularly in cases associated with EV-A71.² EV-A71 was first identified in 1969 in California, USA³ and has become more predominant across the Asia–Pacific region in the past 15 years.^{4–11}

China established a national enhanced surveillance system for HFMD in May 2008 partly in response to several large HFMD outbreaks during 2007 and early 2008.⁹ Here we describe the enhanced HFMD surveillance system and characterize the epidemiology of the disease in China, focusing on age, seasonal, and geographic patterns from 2008 to 2012.

Methods

Enhanced national surveillance program

Beginning on January 1, 2008, all probable and laboratory–confirmed HFMD cases were reported on a voluntary basis to the Chinese Centre for Disease Control and Prevention (China CDC) in Beijing. On May 2, 2008, HFMD was made statutorily notifiable.

Case definitions

A probable HFMD case was defined as a patient with papular or vesicular rash on hands, feet, mouth, or buttocks, with or without fever. A confirmed case was defined as a probable case with laboratory evidence of enterovirus infection (including EV-A71, coxsackievirus A16 (CA-V16), or other non-EV-A71 and non-CA-V16 enteroviruses) detected by reverse-transcriptase polymerase chain reaction (RT-PCR), real-time RT-PCR, or virus isolation.

HFMD patients, whether probable or confirmed, were classified as severe if they experienced any neurological complications (aseptic meningitis, encephalitis, encephalomyelitis, acute flaccid paralysis, or autonomic nervous system dysregulation) and/or cardiopulmonary complications (pulmonary oedema, pulmonary haemorrhage, or cardiorespiratory failure); otherwise, they were categorized as mild cases.

Collection and testing of specimens

Given limited laboratory capacity during the first year of enhanced surveillance (from May 2008 through June 2009), clinical samples were collected from the first five mild, probable cases who visited hospital outpatient departments each week in each of 31 Chinese provinces (Appendix Figure 1). We also attempted to collect specimens from all severe cases. With enhanced capacity after June 2009, samples were collected from the first five mild, probable cases who visited hospital outpatient departments each month in each of the 3,074 counties or districts and from all severe cases (Appendix Figure 1).¹² Depending on the symptoms and clinical status of each case, the appropriate clinical specimens, including throat swab, rectal swab, fecal sample, vesicular fluid, and/or cerebrospinal fluid, were collected. Sampling was systematic and did not follow community outbreaks.

Specimens were placed in sterile viral transport medium and sent to provincial- or prefecture-level CDCs (n=425) for PCR or virus isolation, according to standardized protocols disseminated by the national CDC.¹³ Viral ribonucleic acid (RNA) was extracted using available commercial kits (most frequently, QIAamp Viral RNA Mini Kit, Qiagen, Valencia, CA, USA, and Geneaid Viral RNA Mini Kit, Geneaid Biotech, Taiwan China) as per the manufacturer's protocols. RNA from each sample was tested for specific primers and probes that targeted pan-enterovirus, EV-A71, and CA-V16. Testing was carried out in biosafety level 2 facilities. Test results were classified into four categories: enterovirus negative, EV-A71 positive, CA-V16 positive, or positive for another enterovirus without further serotype identification.

A small number of samples underwent virus isolation at provincial-level CDCs. According to national guidelines,¹² at least ten enterovirus strains should be identified in each province every month. Specimens were inoculated into human rhabdomyosarcoma (susceptible to EV-A71 and CA-V16) and Hep-2 (susceptible to other enteroviruses) cells. If cultures showed cytopathic effect (CPE), serotype identification was obtained by sequencing analysis¹⁴. A blind passage was done with all cultures showing no CPE after 7 days.

Clinical and epidemiologic data

Probable and confirmed cases were reported on-line to the national CDC within 24 hours of diagnosis, using a standardized form including basic demographic information (sex, date of birth, and address), case classification (probable or confirmed), severity (mild or severe), death status, date of symptoms onset, date of diagnosis, and date of death (if applicable), and virus type (EV-A71, CA-V16, other enterovirus) for confirmed cases.

Climate, geographic, and demographic data

To analyze the potential drivers of HFMD seasonality, we collected demographic, economic, geographic, and climatic information for all provinces from 2008 to 2012, including: 1) age-specific population denominators, population density, Gross Domestic Product, and Gross Regional Product;¹⁵ 2) latitude and longitude of province capitals; 3) air, rail, road, and boat passenger data;¹⁶ 4) meteorological data including daily temperature, rainfall, relative humidity, air pressure, average vapor pressure, and hours of sunshine (Appendix Text 1 for details).¹⁷ Climate variables were aggregated by season (spring: April–June; autumn: September–November), to reflect the seasonal occurrence of HFMD peaks in surveillance data. The 31 provinces were further grouped into six climatic regions (Appendix Figure 2A).

Data analysis

Disease burden and severity of disease—We included all cases with illness onset from January 1, 2008 through December 31, 2012 in the analysis. We estimated age-specific rates of incidence, severe illness, and mortality by combining probable and confirmed cases. 95% confidence intervals (CIs) for rates were estimated with Poisson methods. For rates with denominator >100,000 and numerator ≥ 20, we calculated 95% CIs assuming a normal distribution. We assessed the geographic distribution of cases across all 31 provinces, grouped into seven regions as shown in Appendix Figure 2B. We estimated the age specific case–severity risk (no. of severe cases/no. of probable and confirmed cases), case–fatality risk (no. of deaths/no. of probable and confirmed cases), and case–fatality risk of severe HFMD cases (no. of deaths/no. of severe cases), overall and stratified by serotype. In serotype-specific analyses, we estimated the number of serotype-specific HFMD cases by applying the distribution of serotypes among specimens positive for enteroviruses and further serotyped to the universe of probable and confirmed cases.

We calculated the distributions of times from illness onset to diagnosis, illness onset to death, and diagnosis to death by virus serotype. To identify predictors for severe or fatal outcomes, we applied logistic regression and backward selection of demographic and geographic variables, time from onset to diagnosis, and virus type (p-value for exclusion 0–10), separately for laboratory-confirmed cases and probable cases. All analyses were carried out using SAS version 9.1 (SAS Institute, Cary, USA).

Geographic patterns and seasonality—To quantify HFMD seasonal patterns by province, we created heatmaps of the proportion of HFMD cases identified in each week of the year.¹⁸ We also fitted seasonal multiple linear regression models to weekly HFMD time series, including time trends and harmonic terms representing annual and semi-annual

periodic cycles (Appendix Text 2).^{18,19} We extracted the amplitude and peak timing of the annual and semi-annual cycles based on model coefficients.¹⁸ The amplitude measures the difference between the maximum and minimum of a seasonal curve.¹⁹ We used multivariate stepwise linear regression to study the association between HFMD seasonal characteristics and putative seasonal drivers, including geography, human mobility patterns, demographic, economic, and climate variables.¹⁸ Epidemiologically relevant HFMD regions were identified by hierarchical clustering using Ward's minimum variance method, and predictors of these regions were identified through discriminant analysis.¹⁸ Time series were standardized for differences in sampling intensity over time and geography by dividing weekly case counts by the annual number of cases.

Results

Incidence description

7,200,092 probable HFMD cases were reported to the China CDC surveillance system during 2008–2012, of which 3·7% were laboratory–confirmed and 0·03% died. The incidence of reported HFMD cases showed a sharp increase since the initiation of surveillance in 2008 (Table 1), due to improvements in reporting and surveillance. Reported disease rates reached a steady state at over 1·2 cases per 1,000 person–years during 2010–2012.

HFMD incidence varied greatly with age, with highest rates in children aged six months to two years (Table 1). The median age of reported cases was 27 months (interquartile range = 18–43 months). Most cases occurred in children below the age of five, and incidence was very low in young infants aged <6 months, older children, and adults. The incidence of HFMD was 1·6 times higher in boys under 5 years than in girls of the same age ($p<0\cdot001$).

EV-A71 predominated among laboratory-confirmed cases, accounting for 45%, 80%, and 93% of mild, severe, and fatal cases respectively (Figure 1). There was little variation in EV-A71 predominance by age (Figure 2A). EV-A71, CA-V16, and other enteroviruses co-circulated throughout the observation period in all regions (Appendix Figure 3).

Clinical course

The median time from illness onset to diagnosis, illness onset to death, and diagnosis to death were 1·5 days (interquartile range: 0·5–2·5 days), 3·5 days (interquartile range: 2·5–4·5 days), and 0·5 day (interquartile range: 0·5–1·5 days) respectively. The probability density distributions of the onset-to-diagnosis, onset-to-death, and diagnosis-to-death intervals were similar between probable and laboratory–confirmed cases of EV-A71 or other enteroviruses (Figure 3). However, CA-V-16 density distributions showed attenuated signal-to-noise ratio given the small number of deaths ($n=25$).

Severity of disease

Overall the case–fatality, case–severity, and severe case–fatality risks were 0·03% (range across years = 0·03–0·05%), 1·1% (range = 0·2–1·6%), and 3·0% (range = 2·6–10·4%) respectively. Illness severity and death were inversely related to age (Table 2 and Figure

2B–2D). Consistently across all age groups, EV-A71 infections were much more severe than CA-V16 infections (Figure 2B–2D). We performed sensitivity analyses on severity estimates by age and viral etiology limited to 2010–2012 (Appendix Figure 4) and only 2012 (Appendix Figure 5), and found results were similar. Multivariate backward logistic regression of laboratory confirmed cases identified several mortality risk factors beyond young age and infection with EV-A71, including rural residence and long onset-to-diagnosis interval. Further, males and rural residents experienced higher risk of severe disease. Including probable cases in the analysis yielded similar risk predictors (Table 2).

Seasonal characteristics

National and province-specific patterns—At the national scale, HFMD showed semi-annual peaks of activity, including a major peak in spring and early summer followed by a smaller peak in autumn, consistent between probable and confirmed time series (Figure 4).

While Southern China experienced two outbreaks of HFMD peaking in May and October of each year, Northern China experienced a single annual peak in June (Figure 5–6). The annual amplitude of HFMD epidemics increased with increasing latitude and semi-annual periodicity was strongest in the South (Figure 5).

Seasonal characteristics by serotype—All enteroviruses exhibited latitudinal gradients in the amplitude of annual and semi-annual epidemics (Appendix Figures 6–8). Annual peak timing of CA-V16 activity occurred earlier than for other enteroviruses ($p<0.001$).

Predictors of HFMD seasonality—Putative predictors of HFMD seasonal characteristics were identified through multivariate stepwise regression (Appendix Table 1). We found that the annual amplitude of epidemics was associated with spring rainfall and spring sunshine in overall and serotype-stratified analyses ($p<0.05$, partial R^2 : 5%–23%; $p<0.05$, 8%–23%, respectively). HFMD peak timing was associated with maximum spring air pressure in overall and serotype-stratified analyses ($p<0.05$, partial R^2 : 4%–12%). Predictors of semi-annual periodicity of HFMD epidemics were more varied. Population and transportation factors were moderately associated with HFMD seasonal characteristics, explaining 1–19% of the variance in epidemic timing and periodicity. Overall, multivariate models explained a moderate-to-high fraction of the variance in HFMD seasonal characteristics through multiple factors (40–92%).

Epidemiological regions—We identified two main geographic regions that share similar HFMD epidemiological characteristics: a northern region (latitude range 35.5°–46.2°N, plus Tibet, $n=14$) and a southern region (19.5°–34.8°N, $n=17$) (Figure 7). Serotype-specific analysis revealed a broadly similar split between Northern and Southern China, with a third epidemiological region including Western provinces identified for EV-A71 and CA-V16 (Appendix Figures 9–11). Discriminant analysis confirmed that climate factors were the dominant predictors of HFMD epidemiological regions (Figure 7C, Appendix Figures 9–11).

Discussion

Our study relies on a large sample of more than 7.2 million HFMD cases reported to the national enhanced surveillance system during 2008–2012 in China and gives the first comprehensive account of the national burden and epidemiology of the disease (panel). The estimated HFMD incidence is 1.2 per 1,000 person-years in China and the disease is responsible for 350–900 reported deaths annually, predominantly among young children. As in other countries, we observed a predominance of EV-A71 serotype among severe cases, with a particularly young median age at infection of 2.3 years. Our large study covers 31 climatologically diverse provinces and suggests that while HFMD cases tend to occur in warmer months of the year throughout the country, peak timing and periodicity of epidemics varies with latitude. All serotypes causing HFMD appear to follow broadly similar geographic gradients, which are moderately associated with climate differences.

The observed age profile of infection is in agreement with reports from other countries,^{4,20–22} and the particularly young mean age at infection suggests that enteroviruses causing HFMD are highly transmissible. Relative sparing of infants younger than six months was most likely due to protection by maternal antibodies.^{23,24} Infection with the causative viruses appears to confer lifelong immunity at least to disease and possibly infection given the virtual absence of adult cases.

Our large-scale analysis of HFMD seasonal patterns identified two main epidemiological regions corresponding to Northern China, where HFMD peaks in summer, and Southern China, which experiences two HFMD peaks in spring and autumn. A highly transmissible, strongly immunizing disease requires constant replenishment of susceptibles to sustain semi-annual, even annual, epidemics. Experience from Asia-Pacific countries has shown biennial²⁵ or triennial^{20,21} outbreaks against a background total fertility rate of 1.3–3 births per woman,²⁶ compared to China's 1.6 births per woman under the longstanding one-child policy.²⁷ In contrast, annual epidemics were reported in Japan and Malaysia,^{6,25} consistent with observed patterns in Northern China, while semi-annual epidemics were reported in Hong Kong SAR, South Taiwan of China, and Vietnam,^{8,10,21} in line with our Southern China data. Further, our data indicate that EV-A71 epidemics occur annually in China, in contrast to Japan and Malaysia where this serotype circulates every three or four years.^{6,25} HFMD periodicity may be complicated by interference between the causative enterovirus serotypes, perhaps associated with cross-serotype immunity. Overall, the drivers of HFMD periodicity are not fully understood and worthy of further study.

Although HFMD seasonal patterns were associated with precipitations, sunshine, temperature, and air pressure, no single climatic variable explained the complexity of HFMD seasonality across China. Our results confirm those of previous time series analyses suggesting a relationship between HFMD and climatic factors in Singapore, Hong-Kong, Southern China, and Japan.^{29–32} Moreover, the occurrence of poliomyelitis, a disease caused by another enterovirus, may be associated with humidity.³³ Humidity was a weak predictor of HFMD seasonal patterns in our large Chinese study, which encompasses a greater diversity of climate zones and populations than previously studied. The HFMD epidemiological patterns in Hainan and Tibet were apparently different from those in the

other provinces (Fig. 4). This divergence could be due to the extreme, unique climate of these two outliers: Hainan is the only tropical region of China; while the climate in Tibet is very particular and complex because of the great altitude. We cannot rule out artefactual surveillance biases, in part due to the lack of financial and human resources (in Tibet in particular). Clearly, more work is needed to clarify the local drivers of HFMD seasonality in South East Asia.

Systematic, population-representative seroepidemiology studies across the age spectrum from mother-infant pairs through the first ten years of life would greatly refine our understanding of HFMD dynamics in different regions. Previous cross-sectional serosurveys have provided age-specific estimates of the cumulative incidence of infection at certain ages.^{34–37} Prospective longitudinal serological studies could provide more detailed information on age-specific incidence of infection and disease, risk factors for infection, and the protection against new infections conferred by previous infections with the same or different viruses. Longitudinal serosurveys were instrumental to elucidate the acquisition of infection and immunity in other complex disease systems involving competition between viruses, which in turn informed vaccination strategies.³⁸

EV-A71 infection in early infancy conferred the gravest risks for clinical severity and fatality.^{21,39} Several candidate vaccines against EV-A71 are currently undergoing regulatory vetting in China.⁴⁰ Whether and how these should be deployed require further assessment of cost-effectiveness, feasibility and contextual considerations in different regions. Transmission models are needed to fully assess the direct and indirect benefits of vaccination, and the risk of serotype replacement given use of a monovalent vaccine.

Our severity data highlight two independent risk factors: 1) each extra day since symptom onset was associated with a 1% higher risk of mortality, and 2) those living in a rural area had a one-quarter excess risk of death from infection. In addition to rural-urban disparity in health care access and advanced life-sustaining technology,⁴¹ widespread and inappropriate use of glucocorticoids and pyrazolones in mild HFMD stages^{42,43} could have precipitated critical illness and death.

Several limitations bear mention. First, as for any common, self-limiting illness, surveillance only captures the tip of the clinical iceberg while most cases go undetected because their condition is asymptomatic, or the patient does not seek formal care, or he/she is not diagnosed and reported. Second, access to and provision of health care as well as technical capacity varied between and sometimes within provinces and there was no formal quality assurance or systematic audit for HFMD surveillance. In particular, we cannot rule out that surveillance bias explained the marked differences in HFMD patterns observed in Hainan and Tibet, relative to other provinces (Fig. 4). Third, data collected during the first year of rollout are likely less reliable than in more recent years. Fourth, we did not have data on mixed enterovirus infections⁴⁴ and were unable to serotype enteroviruses beyond CV-A16 and EV-A71. In particular, we were unable to monitor serotype CV-A6, which has become more predominant in Southern China.⁴⁵ Fifth, some of severe neurological illnesses caused by EV-A71 may have been missed by using a strict HFMD case definition. Sixth, our study

was based on a descriptive analysis of surveillance data. We unfortunately cannot yet determine/estimate a threshold for yearly epidemic –this is beyond the scope of our study.

In conclusion, we found substantial HFMD illness and mortality associated with co-circulating EV-A71, CA-V16, and other enterovirus in China, disproportionately affecting young children aged <5 years. Younger age, infection with EV-A71, and living in rural area are risk factors for severe disease. Our study also uncovered intriguing differences in HFMD seasonality across China, which may be associated with climate. Overall, our study provides robust, population-based, national data to prioritize EV-A71 vaccination and optimize the timing of routine vaccination regionally. Further, our results will serve as a pre-vaccination baseline against which future interventions can be compared. More broadly, further studies are warranted to elucidate the dynamics and immunity patterns of HFMD, a rising public health problem in Asia.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the hospitals, local health departments and Centers for Disease Control and Prevention in China for assistance in coordinating data collection. We also thank Lin Wang for the data cleaning. We are also grateful to the National Health and Family Planning Commission for supporting this study. The views expressed are those of the authors and do not necessarily represent the policy of the China CDC.

Abbreviations

95% CI	95% confidence interval
CA-V16	coxsackievirus A16
CDC	Centre for Disease Control and Prevention
CPE	cytopathic effect
EV-A71	Enterovirus 71
HFMD	Hand-Foot-And-Mouth Disease
RD	rhabdomyosarcoma
RNA	ribonucleic acid
RT-PCR	reverse-transcriptase polymerase chain reaction

References

1. Melnick, JK. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields, BN.; Knipe, DM.; Howley, PM.; Chanlock, RM.; Melnick, JL.; Monath, TP., et al., editors. *Field's virology*. 3rd ed. Lippincott-Raven; Philadelphia: 1996. p. 655-712.
2. Ooi MH, Wong SC, Lewthwaite P, Cardoso MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. *Lancet Neurol*. 2010; 9:1097–105. [PubMed: 20965438]
3. Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. *J Infect Dis*. 1974; 129:304–9. [PubMed: 4361245]

4. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis. 2000; 31:678–83. [PubMed: 11017815]
5. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999; 341:929–35. [PubMed: 10498487]
6. Vol. 33. IASR; Hand, foot and mouth disease in Japan, 2002–2011. Available at: <http://idsc.nih.gov/ja/iasr/33/385/tpc385.html>
7. Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003; 9:78–85. [PubMed: 12533285]
8. Tu PV, Thao NT, Perera D, Huu TK, Tien NT, Thuong TC, et al. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis. 2007; 13:1733–41. [PubMed: 18217559]
9. Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010; 7:94. [PubMed: 20459851]
10. Ma E, Chan KC, Cheng P, Wong C, Chuang SK. The enterovirus 71 epidemic in 2008--public health implications for Hong Kong. Int J Infect Dis. 2010; 14:e775–80. [PubMed: 20599410]
11. Seiff A. Cambodia unravels cause of mystery illness. Lancet. 2012; 380:206. [PubMed: 22826834]
12. China Ministry of Health. [Accessed September 23 2013] Guideline for HFMD public health response. 2009. Available at: http://www.chinacdc.cn/jkzt/crb/szkb/jszl_2275/200906/t20090612_24707.html
13. [Accessed October 25 2013] Protocol of sample collection and laboratory tests for HFMD cases. 2009. Available at: http://www.chinacdc.cn/jkzt/crb/szkb/jszl_2275/200906/W020130106522855465929.pdf
14. Zhang Y, Wang J, Guo W, Wang H, Zhu S, Wang D, et al. Emergence and transmission pathways of rapidly evolving evolutionary branch C4a strains of human enterovirus 71 in the Central Plain of China. PLoS One. 2011; 6:e27895. [PubMed: 22125635]
15. National Bureau of Statistics of China. [Accessed 23 September 2012] National census in China in 2010. Available at: <http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.html>
16. [Accessed June 15 2012] Yearbook of China integrated transport. Available at: <http://www.zgjtj.com/about/?2.html>
17. Climatic Data Center, National Meteorological Information Center, CMA. [Accessed April 04 2013] Available at: <http://data.cma.gov.cn/index.jsp>
18. Yu H, Alonso WJ, Feng L, Tan Y, Shu Y, Yang W, Viboud C. Characterization of regional influenza seasonality patterns in China and implications for vaccination strategies: spatio-temporal modelling of surveillance data. PLoS Med. Nov 19.2013 In Press.
19. Naumova EN, Jagai JS, Matyas B, DeMaria A Jr, MacNeill IB, Griffiths JK. Seasonality in six enterically transmitted diseases and ambient temperature. Epidemiol Infect. 2007; 135:281–92. [PubMed: 17291363]
20. Ang LW, Koh BK, Chan KP, Chua LT, James L, Goh KT. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001–2007. Ann Acad Med Singapore. 2009; 38:106–12. [PubMed: 19271036]
21. Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT. An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg. 2007; 77:188–91. [PubMed: 17620652]
22. Momoki ST. Surveillance of enterovirus infections in Yokohama city from 2004 to 2008. Jpn J Infect Dis. 2009; 62:471–3. [PubMed: 19934543]
23. Wang SM, Ho TS, Lin HC, Lei HY, Wang JR, Liu CC. Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity. Eur J Clin Microbiol Infect Dis. 2012; 31:1219–24. [PubMed: 21983920]

24. Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. *PLoS One*. 2012; 7:e37206. [PubMed: 22662137]
25. Podin Y, Gias EL, Ong F, Leong YW, Yee SF, Yusof MA, et al. Sentinel surveillance for human enterovirus 71 in Sarawak, Malaysia: lessons from the first 7 years. *BMC Public Health*. 2006; 6:180. [PubMed: 16827926]
26. The World Bank. [Accessed February 20 2013] Fertility rate, total (births per woman). Available at: <http://data.worldbank.org/indicator/SP.DYN.TFRT.IN?page=2>
27. Hesketh T, Lu L, Xing ZW. The effect of China's one-child family policy after 25 years. *N Engl J Med*. 2005; 353:1171–6. [PubMed: 16162890]
28. Ma E, Lam T, Chan KC, Wong C, Chuang SK. Changing epidemiology of hand, foot, and mouth disease in Hong Kong, 2001–2009. *Jpn J Infect Dis*. 2010; 63:422–6. [PubMed: 21099093]
29. Hii YL, Rocklov J, Ng N. Short term effects of weather on hand, foot and mouth disease. *PLoS One*. 2011; 6:e16796. [PubMed: 21347303]
30. Ma E, Lam T, Wong C, Chuang SK. Is hand, foot and mouth disease associated with meteorological parameters? *Epidemiol Infect*. 2010; 138:1779–88. [PubMed: 20875200]
31. Onozuka D, Hashizume M. The influence of temperature and humidity on the incidence of hand, foot, and mouth disease in Japan. *Sci Total Environ*. 2011; 410–411:119–25. [PubMed: 22014509]
32. Huang Y, Deng T, Yu S, Gu J, Huang C, Xiao G, et al. Effect of meteorological variables on the incidence of hand, foot, and mouth disease in children: a time-series analysis in Guangzhou, China. *BMC Infect Dis*. 2013; 13:134. [PubMed: 23497074]
33. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. *Am J Epidemiol*. 2010; 172(11):1213–29. [PubMed: 20978089]
34. Zhu Z, Zhu S, Guo X, Wang J, Wang D, Yan D, et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated widely in central and southern China before large-scale outbreaks from 2008. *Virol J*. Nov 4.2010 7:300. [PubMed: 21050463]
35. Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. *PLoS One*. 2012; 7(5):e37206. [PubMed: 22662137]
36. Zeng M, El Khatib NF, Tu S, Ren P, Xu S, Zhu Q, et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. *J Clin Virol*. Apr; 2012 53(4):285–9. [PubMed: 22265829]
37. Yu H, Wang M, Chang H, Lu J, Lu B, Li J, et al. Prevalence of antibodies against enterovirus 71 in children from Lu'an City in Central China. *Jpn J Infect Dis*. 2011; 64(6):528–32. [PubMed: 22116336]
38. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, et al. Rotavirus infections in infants as protection against subsequent infections. *N Engl J Med*. 1996; 335:1022–8. [PubMed: 8793926]
39. Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. *Pediatrics*. 2002; 109:e88. [PubMed: 12042582]
40. Liang Z, Mao Q, Gao F, Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. *Front Med*. 2013; 7:111–21. [PubMed: 23247645]
41. Shi L. Health care in China: a rural-urban comparison after the socioeconomic reforms. *Bull World Health Organ*. 1993; 71:723–36. [PubMed: 8313490]
42. Jiang Q, Yu BN, Ying G, Liao J, Gan H, Blanchard J, et al. Outpatient prescription practices in rural township health centers in Sichuan Province, China. *BMC Health Serv Res*. 2012; 12:324. [PubMed: 22988946]
43. Ma H, He F, Wan J, Jin D, Zhu L, Liu X, et al. Glucocorticoid and pyrazolone treatment of acute fever is a risk factor for critical and life-threatening human enterovirus 71 infection during an outbreak in China, 2008. *Pediatr Infect Dis J*. 2010; 29:524–9. [PubMed: 20104199]
44. Yan XF, Gao S, Xia JF, Ye R, Yu H, Long JE. Epidemic characteristics of hand, foot, and mouth disease in Shanghai from 2009 to 2010: Enterovirus 71 subgenotype C4 as the primary causative

- agent and a high incidence of mixed infections with coxsackievirus A16. *Scand J Infect Dis*. 2012; 44(4):297–305. [PubMed: 22176514]
45. He YQ, Chen L, Xu WB, Yang H, Wang HZ, Zong WP, et al. Emergence, circulation, and spatiotemporal phylogenetic analysis of coxsackievirus a6- and coxsackievirus a10-associated hand, foot, and mouth disease infections from 2008 to 2012 in Shenzhen, China. *J Clin Microbiol*. 2013; 51(11):3560–6. [PubMed: 23966496]

Panel

Systematic review

We searched PubMed with the keywords “Hand, Foot and Mouth Disease”, “EV71”, “enterovirus 71” and “coxsackie virus A” for all journal articles written in English between Jan 1, 1995, and June 30, 2013. In the past 15 years, EV-A71-associated HFMD epidemics have been increasingly reported across the Asia-Pacific region, chronologically including Malaysia,⁴ Taiwan,⁵ Japan,⁶ Singapore,⁷ Vietnam,⁸ mainland China,⁹ Hong Kong SAR,¹⁰ and Cambodia.¹¹ These reports were mostly descriptive, with very few exceptions that estimated epidemiologic parameters, assessed severity or analyzed seasonality. Even fewer had sufficient power to yield definitive conclusions. No previous report had addressed all three sets of interrelated questions. Here we report the largest study to date across a wide geographic expanse through the recently enhanced national surveillance network for HFMD in China.

Interpretation

We described the enhanced HFMD surveillance system, characterized host characteristics, periodicity of epidemics, and geographic patterns from 2008 to 2012. HFMD incidence was 1·2 per 1,000 person-years with 350–900 reported deaths annually during 2009–2012, predominantly among young children. There was strong age dependency, with children aged six months to two years showing the highest rates (Table 1). Boys under five years were 1·6 times more likely than girls of the same age bracket to register disease. Overall the case–fatality, case–severity, and severe case–fatality risks were 0·03%, 1·1%, and 3·0% respectively. Illness severity and death by enterovirus serotype were inversely related to age (Table 2 and Figure 2, panels B–D). The median time from illness onset to diagnosis, from illness onset to death, and from diagnosis to death were 1·5 days (interquartile range: 0·5–2·5 days), 3·5 days (interquartile range: 2·5–4·5 days), and 0·5 day (interquartile range: 0·5–1·5 days) respectively. HFMD tended to occur during the warmer months of the year throughout the country, although peak timing and the periodicity of epidemics varied substantially with latitude, in particular demonstrating stronger semi-annual cycles in southern China compared to annual outbreaks in the north. Seasonal variation was associated with precipitation, sunshine, temperature, and barometric pressure. However, no single climatic variable was sufficient to explain the complexity of HFMD seasonality across China.

Figure 1. Proportions of enterovirus serotypes among laboratory-confirmed HFMD cases by clinical severity, 2008-2012, China

A: based on mild cases. B: based on severe cases who survived, C: based on fatal cases.

Figure 2. Age distribution and clinical severity of probable and laboratory-confirmed (EV-A71, CA-V16 or other enteroviruses) HFMD cases, 2008-2012, China

A: Age distribution of probable and lab-confirmed cases. B: Risk of fatality among cases by age group and viral etiology. C: Risk of severe illness among cases by age group and viral etiology. D: Risk of fatality among severe cases by age group and viral etiology. EV-A71, enterovirus 71; CA-V16, Coxsackievirus A16; mth, months; y, years. Severity estimates in B-D were calculated by extrapolating the serotype distribution among test-positive cases to untested and test-negative cases. That is, the number of mild cases with serotype X (= EV-A71, CA-V16 or other enteroviruses) was estimated to be (no. of mild cases test-positive for serotype X)/(no. of test-positive mild cases) x (no. of mild cases); severe cases were similarly analyzed. Results were similar if only the 2010-2012 or 2012 data were used (Appendix Figures 4&5).

Figure 3. Estimates of onset-to-diagnosis, onset-to-death, and diagnosis-to-death distributions of probable and laboratory-confirmed (EV-A71, CA-V16 or other enteroviruses) HFMD cases, 2008-2012, China

A: Onset-to-diagnosis distribution by viral etiology (n=7,200,092). B: Onset-to-death distribution by viral etiology (n=2457). C: Diagnosis-to-death distribution by viral etiology (n=2457). Note that some intervals are negative because diagnosis occurred after death.

Figure 4. Heatmap of HFMD surveillance data from 2008 to 2012 by Chinese province
 The provinces were ordered by latitude from Northernmost (top) to Southernmost (bottom).
 A: Time series of weekly probable and lab-confirmed HFMD cases, standardized by the number of annual cases. B: Seasonal distribution of HFMD cases, plotted as the median value of proportion of cases in each week of the year from 2008 to 2012. C: Number of HFMD cases by week of illness onset. The insert is a superposition of the number of cases without probable HFMD cases by week of illness onset.

Figure 5. Latitudinal gradients in periodicity and peak timing of HFMD

A: Amplitude of the annual periodicity. B: Annual peak timing. C: Contribution of the semi-annual periodicity, measured by the ratio of the amplitude of the semi-annual periodicity to the sum of the amplitudes of annual and semi-annual periodicities (higher ratio indicates a stronger semi-annual periodicity). Symbol size is proportional to the number of cases in each province. Black solid line represent linear regression fit (regression weighted by mean annual number of HFMD cases). P-values are given on the graphs. Colors represent different climatic zones (black: cold-temperate, blue mid-temperate, green warm-temperate, orange subtropical, red tropical).

Figure 6. Amplitude and timing of primary HFMD epidemics in China

A: Amplitude of the annual cycle from yellow (low) to red (high), as indicated in the legend.

B: Importance of the semi-annual periodicity, measured by the ratio of the amplitude of the semi-annual cycle to the sum of the amplitudes of annual and semi-annual cycles. Pale green indicates strongly annual influenza epidemics, while dark green indicates dominant semi-annual activity. C: Timing of primary annual HFMD peak, in weeks from Jan 1st. Timing is color coded from pale blue to dark blue.

Figure 7. HFMD epidemiological regions and predictors

A: Identified epidemiological regions based on hierarchical clustering, using the Euclidian distance between weekly standardized HFMD time series. Provinces are color-coded by climatic region (black: cold-temperate, blue: mid-temperate, green: warm temperate, orange: subtropical, red: tropical). B: Map of the three epidemiological regions identified in panel A. C: Climate predictors of the two main clusters identified in panel A, based on stepwise discriminant analysis.

Table 1
Estimated rates of incidence, severe illness and mortality amongst all HFMD cases by age group

Age group	Incidence rates (95% confidence interval), per 1,000,000					Severe illness rates (95% confidence interval), per 1,000,000					Mortality rates (95% confidence interval), per 1,000,000				
	2008	2009	2010	2011	2012	2008	2009	2010	2011	2012	2008	2009	2010	2011	2012
Total	369.2 (368.2-370.3)	869.3 (867.8-870.9)	1352.9 (1350.9-1354.9)	1221.3 (1219.5-1223.2)	1616.4 (1614.3-1618.6)	0.9 (0.9-1.0)	10.4 (10.2-10.6)	21.3 (21.0-21.5)	14.1 (13.9-14.3)	15.6 (15.4-15.8)	0.1 (0.1-0.1)	0.3 (0.2-0.3)	0.7 (0.6-0.7)	0.4 (0.4-0.4)	0.4 (0.4-0.5)
<6 months	673.7 (655.5-691.8)	1319.9 (1294.9-1345.0)	2259.6 (2227.1-2292.1)	2372.5 (2338.0-2407.1)	4014.7 (3966.9-4062.5)	3.8 (2.6-5.5)	35.9 (31.7-40.0)	60.5 (55.1-65.8)	45.5 (40.7-50.2)	65.0 (58.9-71.1)	0.6 (0.2-1.5)	2.0 (1.2-3.2)	3.3 (2.2-4.8)	2.4 (1.4-3.7)	1.5 (0.7-2.7)
6-11 months	7186.5 (7132.1-7241.0)	18561.8 (18475.6-18647.9)	28042.1 (27937.1-28147.1)	25539.2 (25435.2-25643.2)	28862.1 (28744.5-28979.7)	27.3 (23.9-30.6)	317.1 (305.9-328.4)	589.6 (574.4-604.8)	336.9 (325.0-348.9)	407.4 (393.4-421.4)	3.8 (2.6-5.2)	10.5 (8.5-12.6)	27.1 (23.9-30.4)	11.5 (9.3-13.7)	13.3 (10.8-15.9)
12-23 months	8180.8 (8137.1-8224.4)	19148.5 (19082.5-19214.4)	29480.4 (29399.1-29561.6)	30215.9 (30130.6-30301.2)	38191.1 (38096.4-38285.8)	26.4 (23.9-28.9)	326.8 (318.2-335.4)	626.1 (614.3-637.9)	457.3 (446.8-467.8)	492.4 (481.6-503.1)	3.2 (2.3-4.1)	8.6 (7.2-10.0)	20.2 (18.1-22.4)	12.9 (11.2-14.7)	15.3 (13.4-17.2)
24-59 months	4760.6 (4741.1-4780.1)	11306.9 (11276.9-11336.8)	16848.0 (16811.4-16884.5)	16815.9 (16777.9-16853.8)	23111.3 (23067.3-23155.3)	8.8 (8.0-9.6)	93.2 (90.5-95.9)	204.8 (200.8-208.8)	163.3 (159.5-167.0)	182.1 (178.2-186.0)	0.6 (0.4-0.9)	1.8 (1.4-2.2)	5.2 (4.6-5.9)	3.9 (3.3-4.5)	4.1 (3.5-4.6)
5-9 years	580.7 (575.3-586.2)	1045.1 (1037.8-1052.4)	1712.0 (1702.8-1721.2)	1565.3 (1556.2-1574.4)	2706.5 (2694.5-2718.5)	0.7 (0.5-0.9)	5.2 (4.7-5.7)	10.4 (9.7-11.1)	8.8 (8.1-9.5)	10.2 (9.5-10.9)	0.0 (0.0-0.1)	0.1 (0.0-0.1)	0.1 (0.1-0.3)	0.1 (0.0-0.2)	0.1 (0.1-0.2)
10-14 years	68.4 (66.7-70.1)	132.3 (129.9-134.7)	216.3 (213.0-219.5)	186.7 (183.5-189.9)	277.2 (273.4-281.0)	0.1 (0.0-0.1)	0.3 (0.2-0.5)	1.1 (0.9-1.4)	0.9 (0.7-1.2)	0.8 (0.6-1.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.1)	0.0 (0.0-0.1)	0.0 (0.0-0.1)
15 years	2.3 (2.2-2.4)	4.1 (4.0-4.2)	6.5 (6.4-6.7)	5.9 (5.8-6.0)	7.7 (7.6-7.9)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)

Table 2
ORs and 95% CIs of severe illness and death among probable cases and laboratory-confirmed HFMD cases

Results from multivariate logistic regression with backward selection of demographic and geographic variables, time from onset to diagnosis, and virus type (p-value for exclusion 0.10).

Characteristics	Lab-confirmed cases N=267942		Probable cases N=6932150	
	No. of cases	Adjusted OR (95% CI)	No. of cases	Adjusted OR (95% CI)
Death				
Enterovirus serotype				
CV-A16	76817	Ref.	NA	
Other enterovirus	56398	4.36 (2.72-6.98)		
EV-A71	134727	34.24 (22.47-52.18)		
Age group				
5 years	22666	Ref.	638925	Ref.
24-59 months	131560	3.44 (2.24-5.28)	3274253	4.00 (2.12-7.55)
6-23 months	111238	8.75 (5.73-13.35)	2941707	8.59 (4.59-16.09)
<6 months	2478	20.46 (12.35-33.90)	77265	14.21 (6.59-30.62)
Residence				
Urban	115828	Ref.	3219524	Ref.
Rural	137162	1.19 (1.07-1.33)	3218311	2.45 (2.06-2.92)
Per day increase of onset-to-diagnosis interval	NA	1.01 (1.01-1.02)	NA	1.02 (1.01-1.02)
Sex				
Female	96934	Ref.	4351763	Ref.
Male	171008	1.00 (0.90-1.11)	2580384	1.28 (1.09-1.52)
Severe illness				
Enterovirus serotype				
CV-A16	76817	Ref.	NA	
Other enterovirus	56398	3.91 (3.70-4.14)		
EV-A71	134727	11.17 (10.64-11.74)		
Age group				
5 years	22666	Ref.	638925	Ref.
24-59 months	131560	1.90 (1.78-2.01)	3274253	1.99 (1.89-2.10)
6-23 months	111238	3.64 (3.43-3.87)	2941707	3.40 (3.22-3.58)
<6 months	2478	5.68 (5.07-6.36)	77265	4.71 (4.33-5.12)
Severe illness				
Residence				
Urban	115828	Ref.	3219524	Ref.
Rural	137162	1.08 (1.05-1.10)	3218311	1.67 (1.64-1.71)
Per day increase of onset-to-diagnosis	NA	1.00 (1.00-1.00)	NA	1.02 (1.01-1.02)

Characteristics	Lab-confirmed cases N=267942		Probable cases N=6932150	
	No. of cases	Adjusted OR (95% CI)	No. of cases	Adjusted OR (95% CI)
interval				
Sex				
Female	96934		4351763	
Male	171008	1.10 (1.07-1.13)	2580384	1.03 (1.01-1.05)

CI, confidence interval; EV-A71, enterovirus 71; CA-V16, Coxsackievirus A16; Ref., reference; NA, not applicable; OR, odds ratio